Regents of the University of California’s Nurix Therapeutics NRIX Stock Holding History

Regents of the University of California’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-204,123	Closed	-$2.86M	–	41
2022 Q1	$2.86M	Hold	204,123	–	–	0.43%	12
2021 Q4	$5.91M	Sell	204,123 -367,089	-64%	-$11.1M	0.83%	11
2021 Q3	$17.1M	Hold	571,212	–	–	2.02%	7
2021 Q2	$15.2M	Buy	+571,212	New	+$16.8M	1.93%	8

Other funds holding NRIX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Regents of the University of California's NRIX Position: Q2 2022 in Review

Regents of the University of California sold out of Nurix Therapeutics (NRIX) in Q2 2022, closing a stake of 204,123 shares — an estimated $2.86M sold.

Regents of the University of California first reported a position in NRIX in Q2 2021 and held it in 4 quarters. The position peaked at $17.1M in Q3 2021. 106 funds tracked by Wall St. Rank hold NRIX as of Q2 2022.

Regents of the University of California reported no remaining Nurix Therapeutics position as of Q2 2022 after selling out during the quarter.
Regents of the University of California sold 204,123 Nurix Therapeutics shares in Q2 2022, an estimated $2.86M.
Regents of the University of California first reported a position in Nurix Therapeutics in Q2 2021 and held it in 4 quarters.
Regents of the University of California's Nurix Therapeutics position peaked at $17.1M in Q3 2021.
106 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2022.

Based on Regents of the University of California's 13F filing for Q2 2022, filed 5 Aug 2022.